Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

DRMA vs OKYO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OKYO Captures Overall Composite Edge (42.8 HOLD vs 42.2 HOLD), While DRMA Leads 3–0 on Growth & Valuation Pillars

OKYO Overall Winner 6-Pillar Tally: DRMA 3 – 0 OKYO (3 Tie) Matrix Metrics: DRMA 1 – 5 OKYO

As of Nov 20, 2026, OKYO Pharma Limited (OKYO) captures the overall head-to-head institutional edge over Dermata Therapeutics, Inc. (DRMA) on higher Unified Composite conviction (42.8/100 HOLD vs. 42.2/100 HOLD) after splitting the core matrix 5–1 (led by composite factor balance), while DRMA wins 3–0 across the 6-pillar growth and valuation breakdown. DRMA trades at $0.51 (N/M Forward P/E, -13082.3% operating margin) versus OKYO at $1.07 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: OKYO earns the overall head-to-head edge with a stronger Unified Composite Score (42.8/100 HOLD vs. DRMA 42.2/100 HOLD) and 1.05β · 76% Vol risk profile, whereas DRMA leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: DRMA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.4); meanwhile OKYO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DRMA vs OKYO
DRMA NASDAQ
Dermata Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$0.51
-4.23% 1D
Market Cap $2.6M
TTM Revenue $74,137
Forward P/E N/M
Beta / 30D Vol 1.09β · 105% Vol
Unified Composite Score
42.2 / 100 HOLD
Tech 35.0 Fund 42.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -22.9%), weak momentum, RSI 27
RSI-14: 27.4 · SMA20: $0.71 · SMA50: $0.90
OKYO NASDAQ Head-to-Head Winner
OKYO Pharma Limited Ordinary Shares
Biological Products, (No Diagnostic Substances)
$1.07
-7.76% 1D
Market Cap $62.7M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.05β · 76% Vol
Unified Composite Score
42.8 / 100 HOLD
Tech 38.0 Fund 54.0 Flow 50.0 Mom 45.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.9%), weak momentum, RSI 32
RSI-14: 31.8 · SMA20: $1.35 · SMA50: $1.38

6-Pillar Scorecard Institutional Category Breakdown (DRMA 3 – 0 OKYO)

Columns: Metric · DRMA · OKYO
1. Valuation Multiples DRMA
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 35.4x N/M
2. Growth & Scale Tie
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $74,137 N/A
Market Cap $2.6M $62.7M
3. Profitability & Quality DRMA
Gross Margin 54.1% N/A
Operating Margin -13082.3% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -241.5% -263.8%
4. Balance Sheet & Cash Flow DRMA
Cash Generation (TTM) -$7.9M EBITDA N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $0.79 Book/Sh · -241.5% ROE $0.23 Book/Sh · -263.8% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DRMA (1) vs OKYO (5)
Institutional Metric DRMA OKYO Criterion Row Edge
Market Capitalization
Scale
$2.6M $62.7M Larger Scale OKYO
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
-13082.3% 0.0% Higher Margin OKYO
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-241.5% -263.8% Higher ROE DRMA
52-Week Range Position
Momentum
0% ($0–$5) 3% ($1–$3) Stronger Trend OKYO
Beta / 30D Volatility
Risk Regime
1.09β · 105% Vol 1.05β · 76% Vol Lower Realized Risk OKYO
Unified Institutional Score
Composite Signal
42.2 / 100 (HOLD) 42.8 / 100 (HOLD) Higher Composite OKYO
Trailing 12M Revenue (USD)
Operating Scale
$74,137 N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
54.1% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 35.4x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$7.9M EBITDA ($0.79 Book/Sh · -241.5% ROE) N/A ($0.23 Book/Sh · -263.8% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OKYO +13.82 pp
DRMA: -41.03% · OKYO: -27.21%
3M Horizon OKYO +40.07 pp
DRMA: -68.74% · OKYO: -28.67%
6M Horizon OKYO +25.2 pp
DRMA: -59.56% · OKYO: -34.36%
1Y Horizon OKYO +32.09 pp
DRMA: -79.12% · OKYO: -47.03%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DRMA vs OKYO. Trailing 12-month operating profitability (DRMA -13082.3% vs OKYO 0.0%) and valuation multiples (DRMA N/M vs OKYO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

DRMA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$74,137
Gross Margin54.1%
Op. Margin-13082.3%
ROE / Fwd P/E-241.5% · N/M
OKYO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-263.8% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DRMA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact DRMA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
OKYO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact OKYO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DRMA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.6M market capitalization and -13082.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
OKYO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $62.7M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ DRMA vs OKYO Key Questions & Quantitative Answers

As of Nov 20, 2026, OKYO Pharma Limited (OKYO) captures the overall head-to-head institutional edge over Dermata Therapeutics, Inc. (DRMA) on higher Unified Composite conviction (42.8/100 HOLD vs. 42.2/100 HOLD) after splitting the core matrix 5–1 (led by composite factor balance), while DRMA wins 3–0 across the 6-pillar growth and valuation breakdown. DRMA trades at $0.51 (N/M Forward P/E, -13082.3% operating margin) versus OKYO at $1.07 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: OKYO earns the overall head-to-head edge with a stronger Unified Composite Score (42.8/100 HOLD vs. DRMA 42.2/100 HOLD) and 1.05β · 76% Vol risk profile, whereas DRMA leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: DRMA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.4); meanwhile OKYO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DRMA and OKYO split Growth & Scale metrics: DRMA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $74,137 TTM revenue (54.1% gross margin, -13082.3% operating margin), compared with OKYO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, DRMA generates $74,137 in USD-normalized revenue versus N/A for OKYO. In operating R&D and SG&A reinvestment, DRMA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OKYO.

DRMA screens cheaper on headline valuation multiples. DRMA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 35.4x EV/Revenue (unreported EBITDA margin), whereas OKYO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DRMA (-241.5% ROE) versus OKYO (-263.8% ROE) capital efficiency.

In options market volatility and institutional positioning, DRMA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.09β · 105% Vol realized risk). By comparison, OKYO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.05β · 76% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.